We have found that low dose naltrexone (LDN) can substantially reduce pain associated with
fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The
purpose of this study is to determine if LDN lowers inflammatory markers in individuals with
fibromyalgia.
We have found that low dose naltrexone (LDN) can substantially reduce pain associated with
fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The
purpose of this study is to determine if LDN lowers inflammatory markers in individuals with
fibromyalgia.
The objectives of this work are threefold:
1. To evaluate the analgesic efficacy of CWI in women discharged within 23 hours of major
breast cancer surgery
2. To evaluate objective indices of patient recovery following anaesthesia and surgery in a
23 hour model of care
3. To evaluate patient satisfaction with their care pathway
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
